Disposition of tin-protoporphyrin and suppression of hyperbilirubinemia in humans

Karl Anderson, C. S. Simionatto, G. S. Drummond, A. Kappas

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Tin (Sn4+)-protoporphyrin, a potent competitive inhibitor of heme degradation to bile pigment, was cleared rapidly from plasma in normal subjects (t( 1/2 ) ~4 hours for plasma levels >5 nmol/ml, with evidence of dose-dependent pharmacokinetics at lower plasma concentrations). Small amounts were excreted promptly in urine (0.1% to 5.6%) and more gradually in feces (3.7% to 11.3%). The only dose-limiting (>1.0 μmol/kg, single dose) side effect was mild sensitivity to sunlight and long-wave ultraviolet light. Absorption after intramuscular administration was rapid, but there was no absorption after oral dosing. In bile duct-ligated rats treated with Sn-protoporphyrin, there was a substantial (approximately 50%) reduction in plasma bilirubin levels compared with levels in ligated control animals. Seven studies were carried out in four women with moderate to severe cholestasis secondary to primary biliary cirrhosis and in two men with Gilbert's syndrome. In these studies Sn-protoporphyrin (total doses of 0.25 to 2.0 μmol/kg body weight) reduced plasma bilirubin levels to a varying degree (7% to 43%) promptly after its intravenous administration.

Original languageEnglish
Pages (from-to)510-520
Number of pages11
JournalClinical Pharmacology and Therapeutics
Volume39
Issue number5
StatePublished - 1986
Externally publishedYes

Fingerprint

Hyperbilirubinemia
Bilirubin
Gilbert Disease
Bile Pigments
Biliary Liver Cirrhosis
Sunlight
Cholestasis
Ultraviolet Rays
Bile Ducts
Heme
Feces
Intravenous Administration
Pharmacokinetics
Body Weight
tin protoporphyrin IX
Urine

ASJC Scopus subject areas

  • Pharmacology

Cite this

Disposition of tin-protoporphyrin and suppression of hyperbilirubinemia in humans. / Anderson, Karl; Simionatto, C. S.; Drummond, G. S.; Kappas, A.

In: Clinical Pharmacology and Therapeutics, Vol. 39, No. 5, 1986, p. 510-520.

Research output: Contribution to journalArticle

Anderson, Karl ; Simionatto, C. S. ; Drummond, G. S. ; Kappas, A. / Disposition of tin-protoporphyrin and suppression of hyperbilirubinemia in humans. In: Clinical Pharmacology and Therapeutics. 1986 ; Vol. 39, No. 5. pp. 510-520.
@article{22cd0343400440ba9e0eca4e567c3cd1,
title = "Disposition of tin-protoporphyrin and suppression of hyperbilirubinemia in humans",
abstract = "Tin (Sn4+)-protoporphyrin, a potent competitive inhibitor of heme degradation to bile pigment, was cleared rapidly from plasma in normal subjects (t( 1/2 ) ~4 hours for plasma levels >5 nmol/ml, with evidence of dose-dependent pharmacokinetics at lower plasma concentrations). Small amounts were excreted promptly in urine (0.1{\%} to 5.6{\%}) and more gradually in feces (3.7{\%} to 11.3{\%}). The only dose-limiting (>1.0 μmol/kg, single dose) side effect was mild sensitivity to sunlight and long-wave ultraviolet light. Absorption after intramuscular administration was rapid, but there was no absorption after oral dosing. In bile duct-ligated rats treated with Sn-protoporphyrin, there was a substantial (approximately 50{\%}) reduction in plasma bilirubin levels compared with levels in ligated control animals. Seven studies were carried out in four women with moderate to severe cholestasis secondary to primary biliary cirrhosis and in two men with Gilbert's syndrome. In these studies Sn-protoporphyrin (total doses of 0.25 to 2.0 μmol/kg body weight) reduced plasma bilirubin levels to a varying degree (7{\%} to 43{\%}) promptly after its intravenous administration.",
author = "Karl Anderson and Simionatto, {C. S.} and Drummond, {G. S.} and A. Kappas",
year = "1986",
language = "English",
volume = "39",
pages = "510--520",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Disposition of tin-protoporphyrin and suppression of hyperbilirubinemia in humans

AU - Anderson, Karl

AU - Simionatto, C. S.

AU - Drummond, G. S.

AU - Kappas, A.

PY - 1986

Y1 - 1986

N2 - Tin (Sn4+)-protoporphyrin, a potent competitive inhibitor of heme degradation to bile pigment, was cleared rapidly from plasma in normal subjects (t( 1/2 ) ~4 hours for plasma levels >5 nmol/ml, with evidence of dose-dependent pharmacokinetics at lower plasma concentrations). Small amounts were excreted promptly in urine (0.1% to 5.6%) and more gradually in feces (3.7% to 11.3%). The only dose-limiting (>1.0 μmol/kg, single dose) side effect was mild sensitivity to sunlight and long-wave ultraviolet light. Absorption after intramuscular administration was rapid, but there was no absorption after oral dosing. In bile duct-ligated rats treated with Sn-protoporphyrin, there was a substantial (approximately 50%) reduction in plasma bilirubin levels compared with levels in ligated control animals. Seven studies were carried out in four women with moderate to severe cholestasis secondary to primary biliary cirrhosis and in two men with Gilbert's syndrome. In these studies Sn-protoporphyrin (total doses of 0.25 to 2.0 μmol/kg body weight) reduced plasma bilirubin levels to a varying degree (7% to 43%) promptly after its intravenous administration.

AB - Tin (Sn4+)-protoporphyrin, a potent competitive inhibitor of heme degradation to bile pigment, was cleared rapidly from plasma in normal subjects (t( 1/2 ) ~4 hours for plasma levels >5 nmol/ml, with evidence of dose-dependent pharmacokinetics at lower plasma concentrations). Small amounts were excreted promptly in urine (0.1% to 5.6%) and more gradually in feces (3.7% to 11.3%). The only dose-limiting (>1.0 μmol/kg, single dose) side effect was mild sensitivity to sunlight and long-wave ultraviolet light. Absorption after intramuscular administration was rapid, but there was no absorption after oral dosing. In bile duct-ligated rats treated with Sn-protoporphyrin, there was a substantial (approximately 50%) reduction in plasma bilirubin levels compared with levels in ligated control animals. Seven studies were carried out in four women with moderate to severe cholestasis secondary to primary biliary cirrhosis and in two men with Gilbert's syndrome. In these studies Sn-protoporphyrin (total doses of 0.25 to 2.0 μmol/kg body weight) reduced plasma bilirubin levels to a varying degree (7% to 43%) promptly after its intravenous administration.

UR - http://www.scopus.com/inward/record.url?scp=0022578955&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022578955&partnerID=8YFLogxK

M3 - Article

VL - 39

SP - 510

EP - 520

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 5

ER -